A new study reveals a potential breakthrough in controlling the Epstein-Barr virus (EBV), a common herpesvirus carried by an estimated 95% of the global adult population. While often asymptomatic, EBV is linked to several serious conditions, including multiple sclerosis and certain cancers. Researchers have identified a key viral protein, EBNA2, that the virus uses to hijack human B-cells and establish lifelong latency. By developing a compound that specifically inhibits this protein’s interaction with human DNA, scientists were able to block the virus’s ability to immortalize these cells in laboratory models. This targeted approach aims to disrupt the virus’s life cycle without broadly suppressing the immune system, offering a potential path to new therapies for EBV-associated diseases. Further research is needed to develop this discovery into safe and effective treatments for humans. Read the full article at: https://www.sciencedaily.com/releases/2026/04/260414075650.htm